Израел - Хебрејски - Ministry of Health

kamada ltd - immunoglobulin normal human 5 %w/v - liquid - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiency severe combined immunodeficiency wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenic purpura (itp) in children or adults at high risk of bleeding spontaneously or prior to surgery to correct the platelet count guillain barre syndrome and kawasaki disease. allogeneic bone marrow transplantation.

Израел - Хебрејски - Ministry of Health

kamada ltd, israel - cytomegalovirus antibody; human plasma protein; immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 96 %; human plasma protein 50 mg/ml; cytomegalovirus antibody 100 u/ml - cytomegalovirus immunoglobulin

Израел - Хебрејски - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - תמיסה לאינפוזיה - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.

Израел - Хебрејски - Ministry of Health

טבע ליין - חפיפת שיער

Израел - Хебрејски - Ministry of Health

אדוארד גאונט מעבדות קוסמטיקה בעמ - קרם פנים

Израел - Хебрејски - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Израел - Хебрејски - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

Израел - Хебрејски - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

Израел - Хебрејски - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n